Literature DB >> 16226260

Neprylisin decreases uniformly in Alzheimer's disease and in normal aging.

Roberta Russo1, Roberta Borghi, William Markesbery, Massimo Tabaton, Alessandra Piccini.   

Abstract

The proteolysis of beta-amyloid (Abeta) requires neprylisin, an enzyme that has been shown as reduced in Alzheimer's disease (AD). We investigated whether a decrease in neprilysin levels contributes to the accumulation of amyloid deposits not only in AD but also in the normal aging. We analyzed neprilysin mRNA and protein levels in cerebral cortex from 10 cognitively normal elderly subjects with amyloid plaques (NA), 10 cases of AD, and 10 control cases free of amyloid plaques. We found a significant decrease in neprilysin mRNA levels in both AD and NA compared to control cases. Thereby, the defect of neprilysin appears to correlate with Abeta deposition but not with degeneration and dementia.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16226260     DOI: 10.1016/j.febslet.2005.09.054

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  29 in total

1.  Altered NEP2 expression and activity in mild cognitive impairment and Alzheimer's disease.

Authors:  Jeffrey Y Huang; Daniel M Hafez; Bryan D James; David A Bennett; Robert A Marr
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

2.  Loss of neprilysin function promotes amyloid plaque formation and causes cerebral amyloid angiopathy.

Authors:  Wesley Farris; Sonja G Schütz; John R Cirrito; Ganesh M Shankar; Xiaoyan Sun; Ana George; Malcolm A Leissring; Dominic M Walsh; Wei Qiao Qiu; David M Holtzman; Dennis J Selkoe
Journal:  Am J Pathol       Date:  2007-07       Impact factor: 4.307

Review 3.  Amyloid beta-degrading cryptidases: insulin degrading enzyme, presequence peptidase, and neprilysin.

Authors:  E Malito; R E Hulse; W-J Tang
Journal:  Cell Mol Life Sci       Date:  2008-08       Impact factor: 9.261

4.  Pyrrolidine dithiocarbamate attenuates brain Aβ increase and improves long-term neurological outcome in rats after transient focal brain ischemia.

Authors:  Jiejie Li; Wenli Sheng; Chenzhuo Feng; Zhiyi Zuo
Journal:  Neurobiol Dis       Date:  2011-09-24       Impact factor: 5.996

5.  Curcumin inhibits the AKT/NF-κB signaling via CpG demethylation of the promoter and restoration of NEP in the N2a cell line.

Authors:  Yushuang Deng; Xi Lu; Li Wang; Tao Li; Yubin Ding; Huimin Cao; Yuping Zhang; Xiuming Guo; Gang Yu
Journal:  AAPS J       Date:  2014-04-23       Impact factor: 4.009

Review 6.  Recent major advances in cardiovascular pharmacotherapy.

Authors:  James Milner; Andreia Cunha; Carlota Gamboa-Cruz; Julie Reis; Márcia Campos; Natália António
Journal:  Eur J Clin Pharmacol       Date:  2018-03-27       Impact factor: 2.953

Review 7.  The role of microglia in amyloid clearance from the AD brain.

Authors:  C Y Daniel Lee; Gary E Landreth
Journal:  J Neural Transm (Vienna)       Date:  2010-06-15       Impact factor: 3.575

8.  Dynein dysfunction induces endocytic pathology accompanied by an increase in Rab GTPases: a potential mechanism underlying age-dependent endocytic dysfunction.

Authors:  Nobuyuki Kimura; Makoto Inoue; Sachi Okabayashi; Fumiko Ono; Takayuki Negishi
Journal:  J Biol Chem       Date:  2009-09-15       Impact factor: 5.157

9.  Overexpression of neprilysin reduces alzheimer amyloid-beta42 (Abeta42)-induced neuron loss and intraneuronal Abeta42 deposits but causes a reduction in cAMP-responsive element-binding protein-mediated transcription, age-dependent axon pathology, and premature death in Drosophila.

Authors:  Kanae Iijima-Ando; Stephen A Hearn; Linda Granger; Christopher Shenton; Anthony Gatt; Hsueh-Cheng Chiang; Inessa Hakker; Yi Zhong; Koichi Iijima
Journal:  J Biol Chem       Date:  2008-05-07       Impact factor: 5.157

10.  Endothelin-converting enzyme-2 is increased in Alzheimer's disease and up-regulated by Abeta.

Authors:  Jennifer C Palmer; Shabnam Baig; Patrick G Kehoe; Seth Love
Journal:  Am J Pathol       Date:  2009-06-18       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.